Omeros (NASDAQ:OMER) Sees Strong Trading Volume

Shares of Omeros Co. (NASDAQ:OMER) saw unusually-strong trading volume on Wednesday . Approximately 1,324,001 shares were traded during mid-day trading, an increase of 170% from the previous session’s volume of 489,677 shares.The stock last traded at $15.24 and had previously closed at $14.37.

A number of analysts recently commented on OMER shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price (down from $35.00) on shares of Omeros in a research report on Monday. Zacks Investment Research lowered Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, November 16th. Maxim Group set a $32.00 target price on Omeros and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, BidaskClub lowered Omeros from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 12th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $25.40.

The firm has a market cap of $714.91 million, a price-to-earnings ratio of -6.86 and a beta of 2.65. The business has a 50 day simple moving average of $14.79 and a 200-day simple moving average of $16.46.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.08. The company had revenue of $29.86 million for the quarter, compared to analyst estimates of $27.19 million. Omeros’s revenue for the quarter was up 547.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.81) EPS. Equities analysts forecast that Omeros Co. will post -1.13 EPS for the current year.

In other Omeros news, Director Thomas J. Cable sold 5,000 shares of Omeros stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $15.12, for a total transaction of $75,600.00. Following the completion of the transaction, the director now owns 35,067 shares in the company, valued at approximately $530,213.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.80% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Ingalls & Snyder LLC boosted its stake in Omeros by 1.2% during the 3rd quarter. Ingalls & Snyder LLC now owns 5,023,755 shares of the biopharmaceutical company’s stock valued at $82,038,000 after purchasing an additional 58,198 shares during the last quarter. BlackRock Inc. boosted its stake in Omeros by 1.1% during the 2nd quarter. BlackRock Inc. now owns 3,858,463 shares of the biopharmaceutical company’s stock valued at $60,539,000 after purchasing an additional 40,412 shares during the last quarter. Vanguard Group Inc. boosted its stake in Omeros by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 2,401,494 shares of the biopharmaceutical company’s stock valued at $37,679,000 after purchasing an additional 28,991 shares during the last quarter. State Street Corp boosted its stake in Omeros by 1.3% during the 3rd quarter. State Street Corp now owns 1,052,724 shares of the biopharmaceutical company’s stock valued at $17,191,000 after purchasing an additional 13,215 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in Omeros by 9.4% during the 3rd quarter. Stifel Financial Corp now owns 740,959 shares of the biopharmaceutical company’s stock valued at $12,092,000 after purchasing an additional 63,891 shares during the last quarter. Institutional investors and hedge funds own 52.19% of the company’s stock.

Omeros Company Profile (NASDAQ:OMER)

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: Why is total return important?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.